Scarica l'app Stockscreener
0.6905
1.45%
-0.000501
Pasithea Therapeutics Corp Borsa (KTTA) Ultime notizie
What analysts say about Pasithea Therapeutics Corp. Equity Warrant stockExceptional stock performance - Jammu Links News
What analysts say about Pasithea Therapeutics Corp. stockConsistently exceptional gains - Jammu Links News
Why Pasithea Therapeutics Corp. stock attracts strong analyst attentionROI Focused Stock Calls - Newser
How Pasithea Therapeutics Corp. Equity Warrant stock performs during market volatility200 Percent Gain Alert - Newser
How Pasithea Therapeutics Corp. stock performs during market volatilityAI Powered Stock Call - Newser
What makes Pasithea Therapeutics Corp. Equity Warrant stock price move sharplyHigh Return Investment Tips - Newser
Why Pasithea Therapeutics Corp. Equity Warrant stock attracts strong analyst attentionFree Smart Investment Opportunities - Newser
What makes Pasithea Therapeutics Corp. stock price move sharplyDaily Stock Radar - Newser
Pasithea Sets Deadline for Shareholder Proposals - The Globe and Mail
Pasithea Therapeutics schedules 2025 annual meeting for September 3 By Investing.com - Investing.com Nigeria
Pasithea Therapeutics schedules 2025 annual meeting for September 3 - Investing.com
Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board - GlobeNewswire
Nature Journal Author Joins Pasithea to Advance Revolutionary IBD Treatment Research - Stock Titan
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - MSN
Pasithea reports promising phase 1 results for cancer drug By Investing.com - Investing.com South Africa
Pasithea reports promising phase 1 results for cancer drug - Investing.com
Pasithea Therapeutics Reports Promising Interim Results for PAS-004 in Phase 1 Trial for Refractory Solid Tumors at ASCO 2025 - Nasdaq
Pasithea Therapeutics Presents Updated Interim Data from - GlobeNewswire
Breakthrough Cancer Drug Shows 15% Tumor Shrinkage in Melanoma and Pancreatic Cancer Patients in Phase 1 Trial - Stock Titan
Pasithea’s PAS-004 shows promise in inflammatory disease study - Investing.com Australia
Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases - marketscreener.com
Pasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory Diseases - Nasdaq
Pasithea Therapeutics Announces Preclinical Data that Shows - GlobeNewswire
Breakthrough: Novel IBD Drug Outperforms FDA-Approved Treatment in Targeting Key Inflammation Pathway - Stock Titan
Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy - Yahoo Finance
Pasithea Therapeutics CEO sells shares worth $792 - Investing.com
Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site - marketscreener.com
Pasithea Therapeutics Announces Initiation of Phase 1/1B - GlobeNewswire
Phase 1/1b Trial: Pasithea's Once-Daily NF1 Drug Could Outperform Current Treatments - Stock Titan
Pasithea Therapeutics Raises $6.3 Million in Stock Offering - TipRanks
Pasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer Indications - Nasdaq
Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewswire
Pasithea Therapeutics 3.57M share Secondary priced at $1.40 - Yahoo Finance
Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated By Stocktwits - Investing.com India
Pasithea Therapeutics Prices $5 Million Public Offering - marketscreener.com
Pasithea Therapeutics announces interim data from Phase 1 trial of PAS-004 - TipRanks
Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - The Manila Times
Pasithea Therapeutics (KTTA) Skyrockets: Stock Soars Over 115% in Morning Trade - apnakal
$5M Public Offering: Pasithea Therapeutics Advances MEK Inhibitor Drug for Rare Disease Treatment - Stock Titan
0.86%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):